Jupiter Orphan Therapeutics
601 Heritage Drive
About Jupiter Orphan TherapeuticsJupiter Orphan Therapeutics (JOT) is a specialty pharmaceutical company developing therapies for rare diseases linked to single gene deficiencies. JOT, a Delaware Corporation with it's principal office located in Jupiter, FL, USA, was founded in the summer of 2015. In its short period of operations, JOT has assembled a very strong management and scientific team as well as defined five pipeline products which of one is already in Phase II.
Founder and CEO: Christer Rosén
CFO: Jacob Uittenbogaard
Co-Founder and CMO: Dr. Claes Wahlestedt, MD, Ph.D.
CSO: Marshall Hayward
VP of Science Research: Shaun P Brothers, Ph.D. ?? PIPELINE:
Please click here for Jupiter Orphan Therapeutics' pipeline.
17 articles with Jupiter Orphan Therapeutics
Jupiter Orphan Therapeutics Announces First Patient Dosed in Phase I Dose Escalation Study of JOTROL™
Jupiter Orphan Therapeutics, Inc. ("JOT") a biotechnology company pioneering a novel and disease modifying product named JOTROL™, today announced that the first patient has been dosed in a Phase I dose escalation study of JOTROL™
Jupiter Orphan Therapeutics, Inc. announced that its flagship JOTROLTM resveratrol delivery system has been granted patent No. 10780056 by the U.S. Patent & Trademark Office, in addition to its European patents, issued earlier this year.
9/28/2020The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
Jupiter Orphan Therapeutics, Inc., a clinical-stage drug platform company focused on neurological and rare diseases, announced today that the National Institute on Aging at the NIH will award it $1.76 million (over 1 year) to support a Phase I clinical study of JOTROL™, for the treatment of early-stage Alzheimer's disease.
5/8/2020Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Jupiter Orphan Therapeutics, Inc. announced that it is strengthening its Scientific Advisory Board with the addition of Dr. Charbel Moussa, and created a new advisory position in patient advocacy by the appointment of Mark Dant..
Professor Rudolph E. Tanzi, Ph.D., World Renowned Alzheimer's Researcher, Joins Jupiter Orphan Therapeutics
Dr. Tanzi stated "I am excited about being able to work with JOT to bring drugs to patients who need solutions for neurological diseases."
Jupiter Orphan Therapeutics, Inc. Selected to Participate at Upcoming Cavendish BioHealth Impact Forum
Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences
Jupiter Orphan Therapeutics Announces Favorable Data Which Expands JOTROL's Applications to the Estimated $5 Billion Mitochondrial Rare Disease Market
New data regarding an increase in mitochondrial biogenesis in liver and brain from a recently performed study in a frequently studied Alzheimer's disease animal model, the triple transgenic mouse.
Jupiter Orphan Therapeutics, Inc. Adds Professor Gino Cortopassi, Ph.D. to Assist in The Company's Mitochondrial Disease Projects
Jupiter Orphan Therapeutics, Inc. (JOT) today announced that the well-known scientist Gino Cortopassi, Ph.D. joined JOT as a member of its Scientific Advisory Board (SAB).
Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I
Jupiter Orphan Therapeutics, Inc. ("JOT"), Jupiter, FL, today announced that it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI).
This will be the first of several anticipated IND submissions in 2018 utilizing JOT's platform product, JOTROL.
Jupiter Orphan Therapeutics Receives Orphan Drug Designation For Its Trans-Resveratrol Product JOTROL For Treatment Of Friedreich's Ataxia
Catalent To Develop Softgel Capsules For Jupiter Orphan Therapeutics’s Leading Orphan Disease Candidates